Prevalence, Transmission and Genetic Diversity of Pyrazinamide Resistance Among Multidrug-Resistant Mycobacterium tuberculosis Isolates in Hunan, China

References

• World Health Organization. Global Tuberculosis Report. Geneva: World Health 0rganization; 2022.
   Google Scholar
• Zhao Y, Xu S, Wang L, et al. National survey of drug-resistant tuberculosis in China. N Engl J Med. 2012;366(23):2161–2170. doi:10.1056/NEJMoa1108789
   PubMed Web of Science ®Google Scholar
• Singh R, Dwivedi SP, Gaharwar US, et al. Recent updates on drug resistance in mycobacterium tuberculosis. J Appl Microbiol. 2020;128(6):1547–1567. doi:10.1111/jam.14478
   PubMed Web of Science ®Google Scholar
• Kempker RR, Heinrichs MT, Nikolaishvili K, et al. Lung tissue concentrations of pyrazinamide among patients with drug-resistant pulmonary tuberculosis. Antimicrob Agents Chemother. 2017;61(6): doi:10.1128/AAC.00226-17
   Web of Science ®Google Scholar
• Zhang Y, Chiu Chang K, Leung CC, et al. ‘Z(S)-MDR-TB’ versus ‘Z(R)-MDR-TB’: improving treatment of MDR-TB by identifying pyrazinamide susceptibility. Emerg Microbes Infect. 2012;1(7): e5. doi:10.1038/emi.2012.18
   PubMedGoogle Scholar
• Whitfiels MG, Soeters HM, Warren RM, et al. A global perspective on pyrazinamide resistance: systematic review and meta-analysis. PLoS One. 2015;10(7): e0133869. doi:10.1371/journal.pone.0133869
   PubMed Web of Science ®Google Scholar
• Morlock GP, Tyrrell FC, Baynham D, et al. Using reduced inoculum densities of mycobacterium tuberculosis in MGIT pyrazinamide susceptibility testing to prevent false-resistant results and improve accuracy: a multicenter evaluation. Tuberc Res Treat. 2017;2017:3748163. doi:10.1155/2017/3748163
   PubMedGoogle Scholar
• Mustazzolu A, Piersimoni C, Iacobino A, et al. Revisiting problems and solutions to decrease mycobacterium tuberculosis pyrazinamide false resistance when using the bactec MGIT 960 system. Ann Ist Super Sanita. 2019;55(1):51–54. doi:10.4415/ANN_19_01_09
   PubMed Web of Science ®Google Scholar
• Konno K, Feldmann F, McDermott W. Pyrazinamide susceptibility and amidase activity of tubercle bacilli. Am Rev Respir Dis. 1967;95(3):461–469. doi:10.1164/arrd.1967.95.3.461
   PubMed Web of Science ®Google Scholar
• Wayne LG. Simple pyrazinamidase and urease tests for routine identification of mycobacteria. Am Rev Respir. 1974; 109: 147–51.
   PubMed Web of Science ®Google Scholar
• Aono A, Chikamatsu K, Yamada H, et al. A simplified pyrazinamidase test for pyrazinamide drug susceptibility in mycobacterium tuberculosis. J Microbiol Methods. 2018;154:52–54. doi:10.1016/j.mimet.2018.09.018
   PubMed Web of Science ®Google Scholar
• Singh P, Wesley C, Jadaun GP, et al. Comparative evaluation of Lowenstein-Jensen proportion method, bact/ALERT 3D system, and enzymatic pyrazinamidase assay for pyrazinamide susceptibility testing of mycobacterium tuberculosis. J Clin Microbiol. 2007;45(1):76–80. doi:10.1128/JCM.00951-06
   PubMed Web of Science ®Google Scholar
• World Health Organization. WHO operational handbook on tuberculosis: module 3: diagnosis-rapid diagnostics for tuberculosis detection: World Health Organization; 2021.
   Google Scholar
• Li K, Yang Z, Gu J, et al. Characterization of pncA mutations and prediction of PZA resistance in mycobacterium tuberculosis clinical isolates from Chongqing, China. Front Microbiol. 2020;11:594171. doi:10.3389/fmicb.2020.594171
   PubMedGoogle Scholar
• Yadon AN, Maharaj K, Adamson JH, et al. A comprehensive characterization of PncA polymorphisms that confer resistance to pyrazinamide. Nat Commun. 2017;8(1):588. doi:10.1038/s41467-017-00721-2
   PubMedGoogle Scholar
• Miotto P, Cabibbe AM, Feuerriegel S, et al. Mycobacterium tuberculosis pyrazinamide resistance determinants: a multicenter study. mBio. 2014;5(5): e01819–14. doi:10.1128/mBio.01819-14
   PubMed Web of Science ®Google Scholar
• Ei PW, Mon AS, Htwe MM, et al. Pyrazinamide resistance and pncA mutations in drug resistant mycobacterium tuberculosis clinical isolates from Myanmar. Tuberculosis. 2020;125:102013. doi:10.1016/j.tube.2020.102013
   PubMed Web of Science ®Google Scholar
• Naluyange R, Mboowa G, Komakech K, et al. High prevalence of phenotypic pyrazinamide resistance and its association with pncA gene mutations in mycobacterium tuberculosis isolates from Uganda. PLoS One. 2020;15(5): e0232543. doi:10.1371/journal.pone.0232543
   PubMed Web of Science ®Google Scholar
• Shi W, Zhang X, Jiang X, et al. Pyrazinamide inhibits trans-translation in mycobacterium tuberculosis. Science. 2011;333(6049):1630–1632. doi:10.1126/science.1208813
   PubMed Web of Science ®Google Scholar
• Dillon NA, Peterson ND, Feaga HA, et al. Anti-tubercular activity of pyrazinamide is independent of trans-translation and RpsA. Sci Rep. 2017;7(1):6135. doi:10.1038/s41598-017-06415-5
   PubMedGoogle Scholar
• Liu W, Chen J, Shen Y, et al. Phenotypic and genotypic characterization of pyrazinamide resistance among multidrug-resistant mycobacterium tuberculosis clinical isolates in Hangzhou, China. Clin Microbiol Infect. 2018;24(9): e1–1016 e5. doi:10.1016/j.cmi.2017.12.012
   PubMed Web of Science ®Google Scholar
• Khan MT, Rehaman AU, Junaid M, et al. Insight into novel clinical mutants of RpsA-S324F, E325K, and G341R of Mycobacterium tuberculosis associated with pyrazinamide resistance. Comput Struct Biotechnol J. 2018;16:379–387. doi:10.1016/j.csbj.2018.09.004
   PubMed Web of Science ®Google Scholar
• Khan MT, Khan A, Rehman AU, et al. Structural and free energy landscape of novel mutations in ribosomal protein S1 (rpsA) associated with pyrazinamide resistance. Sci Rep. 2019;9(1):7482. doi:10.1038/s41598-019-44013-9
   PubMedGoogle Scholar
• Tan Y, Hu Z, Zhang T, et al. Role of pncA and rpsA gene sequencing in detection of pyrazinamide resistance in Mycobacterium tuberculosis isolates from southern China. J Clin Microbiol. 2014;52(1):291–297. doi:10.1128/JCM.01903-13
   PubMed Web of Science ®Google Scholar
• Xia Q, Zhao LL, Li F, et al. Phenotypic and genotypic characterization of pyrazinamide resistance among multidrug-resistant Mycobacterium tuberculosis isolates in Zhejiang, China. Antimicrob Agents Chemother. 2015;59(3):1690–1695. doi:10.1128/AAC.04541-14
   PubMed Web of Science ®Google Scholar
• Zhang S, Chen J, Shi W, et al. Mutations in panD encoding aspartate decarboxylase are associated with pyrazinamide resistance in Mycobacterium tuberculosis. Emerg Microbes Infect. 2013;2(6):e34. doi:10.1038/emi.2013.38
   PubMed Web of Science ®Google Scholar
• Gopal P, Sarathy JP, Yee M, et al. Pyrazinamide triggers degradation of its target aspartate decarboxylase. Nat Commun. 2020;11(1):1661. doi:10.1038/s41467-020-15516-1
   PubMed Web of Science ®Google Scholar
• Shi J, Su R, Zheng D, et al. Pyrazinamide resistance and mutation patterns among multidrug-resistant mycobacterium tuberculosis from Henan Province. Infect Drug Resist. 2020;13:2929–2941. doi:10.2147/IDR.S260161
   PubMed Web of Science ®Google Scholar
• Burgos MV, Pym AS. Molecular epidemiology of tuberculosis. Eur Respir J Suppl. 2002;36(Supplement 36):54s–65s. doi:10.1183/09031936.02.00400702
   PubMedGoogle Scholar
• Eva Nathanson MS, Paul Nunn FRCP, Mukund Uplekar MD, et al. MDR Tuberculosis — critical Steps for Prevention and Control. New Engl J Med. 2010;363 (11) : 1050 -8. doi:10.1056/NEJMra0908076
   PubMed Web of Science ®Google Scholar
• Che Y, Bo D, Lin X, et al. Phenotypic and molecular characterization of pyrazinamide resistance among multidrug-resistant mycobacterium tuberculosis isolates in Ningbo, China. BMC Infect Dis. 2021;21(1):605. doi:10.1186/s12879-021-06306-1
   PubMed Web of Science ®Google Scholar
• Alene KA, Xu Z, Bai L, et al. Spatial clustering of drug-resistant tuberculosis in Hunan province, China: an ecological study. BMJ Open. 2021;11(4): e043685. doi:10.1136/bmjopen-2020-043685
   PubMed Web of Science ®Google Scholar
• World health Organization. Policy guidance on drug-susceptibility testing (DST) of second-line antituberculosis drugs. World health Organization;2008.
   Google Scholar
• World health Organization. Technical report on critical concentrations for drug susceptibility testing of medicines used in the treatment of drug-resistant tuberculosis. World health Organization;.2018.
   Google Scholar
• Wayne LG. Simple pyrazinamidase and urease tests for routine identification of mycobacteria. Am Rev Respir Dis. 1974;109(1):147–151. doi:10.1164/arrd.1974.109.1.147
   PubMedGoogle Scholar
• World Health Organization. Catalogue of Mutations in Mycobacterium Tuberculosis Complex and Their Association with Drug Resistance. Geneva: World Health Organization; 2021.
   Google Scholar
• Supply P, Allix C, Lesjean S, et al. Proposal for standardization of optimized mycobacterial interspersed repetitive unit-variable-number tandem repeat typing of mycobacterium tuberculosis. J Clin Microbiol. 2006;44(12):4498–4510. doi:10.1128/JCM.01392-06
   PubMed Web of Science ®Google Scholar
• Pang Y, Zhu D, Zheng H, et al. Prevalence and molecular characterization of pyrazinamide resistance among multidrug-resistant mycobacterium tuberculosis isolates from Southern China. BMC Infect Dis. 2017;17(1):711. doi:10.1186/s12879-017-2761-6
   PubMed Web of Science ®Google Scholar
• Gu Y, Yu X, Jiang G, et al. Pyrazinamide resistance among multidrug-resistant tuberculosis clinical isolates in a national referral center of China and its correlations with pncA, rpsA, and panD gene mutations. Diagn Microbiol Infect Dis. 2016;84(3):207–211. doi:10.1016/j.diagmicrobio.2015.10.017
   PubMed Web of Science ®Google Scholar
• Pwasmmsmktllnn E. Pyrazinamide resistance and pncA mutations in drug resistant mycobacterium tuberculosis clinical isolates from Myanmar. Tuberculosis. 2020;125: doi:10.1016/j.tube.2020.102013
   Web of Science ®Google Scholar
• Calderon RI, Velasquez GE, Becerra MC, et al. Prevalence of pyrazinamide resistance and Wayne assay performance analysis in a tuberculosis cohort in Lima, Peru. Int J Tuberc Lung Dis. 2017;21(8):894–901. doi:10.5588/ijtld.16.0850
   PubMed Web of Science ®Google Scholar
• Park S, Jo KW, Shim TS. Treatment outcomes in multidrug-resistant tuberculosis according to pyrazinamide susceptibility. Int J Tuberc Lung Dis. 2020;24(2):233–239. doi:10.5588/ijtld.19.0314
   PubMed Web of Science ®Google Scholar
• Alame-Emane AKXP, Pierre-Audigier C, Cadet-Daniel V, et al. Pyrazinamide resistance in mycobacterium tuberculosis arises after rifampicin and fluoroquinolone resistance. Int J Tuberc Lung Dis. 2015;19(6):679–684. doi:10.5588/ijtld.14.0768
   PubMed Web of Science ®Google Scholar
• Daum LT, Konstantynovska OS, Solodiankin OS, et al. Characterization of novel Mycobacterium tuberculosis pncA gene mutations in clinical isolates from the Ukraine. Diagn Microbiol Infect Dis Apr. 2019;93(4):334–338. doi:10.1016/j.diagmicrobio.2018.10.018
   PubMed Web of Science ®Google Scholar
• Sengstake S, Bergval IL, Schuitema AR, et al. Pyrazinamide resistance-conferring mutations in pncA and the transmission of multidrug resistant TB in Georgia. BMC Infect Dis. 2017;17(1):491. doi:10.1186/s12879-017-2594-3
   PubMedGoogle Scholar
• Rajendran V, Sethumadhavan R. Drug resistance mechanism of PncA in Mycobacterium tuberculosis. J Biomol Struct Dyn. 2014;32(2):209–221. doi:10.1080/07391102.2012.759885
   PubMed Web of Science ®Google Scholar
• Jonmalung J, Prammananan T, Leechawengwongs M, et al. Surveillance of pyrazinamide susceptibility among multidrug-resistant mycobacterium tuberculosis isolates from Siriraj Hospital, Thailand. BMC Microbiol. 2010;10(1):223. doi:10.1186/1471-2180-10-223
   PubMedGoogle Scholar
• Rueda D, Bernard C, Gandy L. susceptibility in Mycobacterium tuberculosis. Int J Mycobacteriol. 2018;7(1):16–25. doi:10.4103/ijmy.ijmy_187_17
   PubMedGoogle Scholar
• Ramirez-Busby SM, Rodwell TC, Fink L, et al. A multinational analysis of mutations and heterogeneity in PZase, RpsA, and PanD associated with pyrazinamide resistance in M/XDR mycobacterium tuberculosis. Sci Rep. 2017;7(1):3790. doi:10.1038/s41598-017-03452-y
   PubMedGoogle Scholar
• Karmakar M, Rodrigues CHM, Horan K, et al. Structure guided prediction of pyrazinamide resistance mutations in pncA. Sci Rep. 2020;10(1):1875. doi:10.1038/s41598-020-58635-x
   PubMed Web of Science ®Google Scholar
• Suzuki S, Horinouchi T, Furusawa C. Prediction of antibiotic resistance by gene expression profiles. Nat Commun. 2014;5(1):5792. doi:10.1038/ncomms6792
   PubMedGoogle Scholar
• Vallejos-Sanchez K, Lopez JM, Antiparra R, et al. Mycobacterium tuberculosis ribosomal protein S1 (RpsA) and variants with truncated C-terminal end show absence of interaction with pyrazinoic acid. Sci Rep. 2020;10(1):8356. doi:10.1038/s41598-020-65173-z
   PubMedGoogle Scholar
• Gopal P, Nartey W, Ragunathan P, et al. Pyrazinoic acid inhibits mycobacterial coenzyme a biosynthesis by binding to aspartate decarboxylase PanD. ACS Infect Dis. 2017;3(11):807–819. doi:10.1021/acsinfecdis.7b00079
   PubMed Web of Science ®Google Scholar
• World health Organization. High-Priority Target Product Profiles for New Tuberculosis Diagnostics: Report of a Consensus Meeting. Geneva: World Health Organization; 2014.
   Google Scholar